Jianmin Pharmaceutical Group Co.,Ltd.
Shanghai Stock ExchangeTotal Valuation
Jianmin Pharmaceutical Group Co.,Ltd. carries a market capitalization of 4.43B, placing it among publicly traded companies globally. Its enterprise value stands at 4.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.43B |
| Enterprise Value | 4.99B |
Share Statistics
Jianmin Pharmaceutical Group Co.,Ltd. currently has 153.40M shares outstanding.
| Shares Outstanding | 153.40M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Jianmin Pharmaceutical Group Co.,Ltd. trades at a trailing price-to-earnings ratio of 17.23. The price-to-sales ratio is 1.79, and the price-to-book ratio stands at 3.20.
| PE Ratio | 17.23 |
| PS Ratio | 1.79 |
| PB Ratio | 3.20 |
| P/TBV Ratio | 2.39 |
| P/FCF Ratio | 53.04 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Jianmin Pharmaceutical Group Co.,Ltd. trades at an EV/EBITDA multiple of 22.17 and an EV/FCF ratio of 39.53. The EV/Sales ratio of 1.51 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.17 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.51 |
| EV / EBITDA | 22.17 |
| EV / EBIT | 22.17 |
| EV / FCF | 39.53 |
Financial Position
Jianmin Pharmaceutical Group Co.,Ltd. maintains a current ratio of 1.56, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.61, indicating elevated leverage, while an interest coverage ratio of 14.40 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.56 |
| Quick Ratio | 0.63 |
| Debt / Equity | 4.61 |
| Debt / EBITDA | 0.52 |
| Interest Coverage | 14.40 |
Financial Efficiency
Jianmin Pharmaceutical Group Co.,Ltd. posts a return on equity of 19.68 and a return on invested capital of 8.20.
| Return on Equity (ROE) | 19.68 |
| Return on Assets (ROA) | 8.18 |
| Return on Invested Capital (ROIC) | 8.20 |
| Return on Capital Employed (ROCE) | 18.75 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.92 |
Taxes
Over the trailing twelve months, Jianmin Pharmaceutical Group Co.,Ltd. has paid 22.17M in income taxes, reflecting an effective tax rate of 5.97.
| Income Tax | 22.17M |
| Effective Tax Rate | 5.97 |
Stock Price Statistics
Jianmin Pharmaceutical Group Co.,Ltd.'s stock has declined approximately -25.95439% over the past 52 weeks. The 50-day moving average sits at 29.51, while the 200-day moving average is 34.17.
| Beta (5Y) | N/A |
| 52-Week Price Change | -25.95439% |
| 50-Day Moving Average | 29.51 |
| 200-Day Moving Average | 34.17 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Jianmin Pharmaceutical Group Co.,Ltd. generated 3.30B in revenue and converted that into 343.45M in net income, yielding earnings per share of 2.31. EBITDA reached 225.10M, while operating income came in at 225.10M.
| Revenue | 3.30B |
| Gross Profit | 1.88B |
| Operating Income | 225.10M |
| Pretax Income | 371.24M |
| Net Income | 343.45M |
| EBITDA | 225.10M |
| EBIT | 225.10M |
| Earnings Per Share (EPS) | 2.31 |
Balance Sheet
Jianmin Pharmaceutical Group Co.,Ltd. holds 1.06B in cash and equivalents against 116.65M in total debt, resulting in a net debt position of -89.03M. Total book value stands at 1.85B, with working capital of 945.46M providing operational flexibility.
| Cash & Cash Equivalents | 1.06B |
| Total Debt | 116.65M |
| Net Debt | -89.03M |
| Equity (Book Value) | 1.85B |
| Book Value Per Share | 12.24 |
| Working Capital | 945.46M |
Cash Flow
After subtracting -111.57M in capital expenditures, free cash flow totaled -111.57M - equivalent to -0.74 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -111.57M |
| Free Cash Flow | -111.57M |
| FCF Per Share | -0.74 |
Margins
Jianmin Pharmaceutical Group Co.,Ltd. operates with a gross margin of 57.02, reflecting its pricing power and cost economics. The operating margin of 6.82 and net profit margin of 10.41 provide insight into operational efficiency.
| Gross Margin | 57.02 |
| Operating Margin | 6.82 |
| Pretax Margin | 11.25 |
| Profit Margin | 10.41 |
| EBITDA Margin | 6.82 |
Dividends & Yields
The company's payout ratio of 39.96 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.94 |
| Dividend Yield | N/A |
| Payout Ratio | 39.96 |
| Shareholder Yield | 2.25 |
| FCF Yield | 1.89 |
Stock Splits
Jianmin Pharmaceutical Group Co.,Ltd.'s most recent stock split took place on July 12, 2006 with a 1:2 split ratio.
| Last Split Date | 7/12/2006 |
| Split Ratio | 1:2 |
Scores
Jianmin Pharmaceutical Group Co.,Ltd. posts an Altman Z-Score of 3.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.75 |